Syndax Pharmaceuticals shares rise 2.82% premarket after UBS adjusted price target.

Syndax Pharmaceuticals, Inc. rose 2.82% in premarket trading. UBS adjusted its price target on Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing a pipeline of cancer therapies. The company is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged acute leukemias, and axatilimab, a monoclonal antibody.